

Earnings Presentation

Q3 2023



Global Digital Manufacturing Locations



Forward-looking Statements and Non-GAAP Measures

- · These slides may contain forward-looking statements. These statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results. levels of activity, performance, or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forwardlooking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results, levels of activity, performance, or achievements.
- Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in Protolabs' SFC filings, including the annual Form 10-K filings and the quarterly Form 10-Q filings. If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement you see or hear during this presentation reflects our current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, growth strategy, and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.
- Non-GAAP Financial Measures: Protolabs management believes that presenting certain non-GAAP financial measures provides meaningful information to investors in understanding operating results and may enhance investors' ability to analyze financial and business trends. Non-GAAP measures are not a substitute for GAAP measures and should be considered together with the GAAP financial measures. As calculated, our non-GAAP measures may not be comparable to other similarly titled measures of other companies. In addition, Protolabs management believes that these non-GAAP financial measures allow investors to compare period to period more easily by excluding items that could have a disproportionately negative or positive impact on results in any particular period, GAAP to non-GAAP reconciliations are included in this presentation.



2023 Priorities - Q3 Update



2023 Priorities – Q3 Update

Priority Growth Areas – IM and CNC

Injection Molding

- Year-to-date, IM revenue is up in constant currencies and excluding Japan
 - We believe we will achieve our goal of YoY IM growth for the full year 2023
- Combined factory and network offer gaining traction; winning larger orders
- CNC Machining integrated comprehensive offer powered by Hubs network
 - Year-to-date, CNC machining revenue is up in constant currencies and excluding Japan
 - We believe we will achieve YoY CNC machining growth for the full year 2023
 - Significant portion of year-to-date CNC machining growth driven by legacy Protolabs customers ordering parts fulfilled through the network



2023 Priorities – Q3 Update (continued)

Shareholder Value Creation / Profitability Expansion

- Third quarter financial results:
 - Record quarterly total revenue
 - Record quarterly network revenue
 - Highest quarterly consolidated gross profit since 2019
 - Highest quarterly Non-GAAP* earnings per share since 2020
 - Three straight quarters of gross and operating margin expansion
- Strong cash flow generation \$24M in cash from operations in Q3 2023
- Continued to return capital to shareholders through share repurchases (\$9M)



Customer Value Examples



Fortune 500 Medical Company

Protolabs' comprehensive model provides immense value

CHALLENGE

- Fortune 500 medical company had a line-down situation at an existing vendor, leaving it with a large gap in delivery of its end-use production equipment for surgical rooms
- Company needed quick-turn machined components

SOLUTION

- Customer is a regular Protolabs IM customer, and was aware of our speed and reliability; it leveraged the digital factory for prototype run of machined parts
- Due to part complexity, production shifted to our digital network
- Digital network manufactured and delivered more than \$500,000 in production-grade, enduse components over the course of a few months

VALUE DELIVERED

 Combination of factory and network capabilities provided value by helping customer avoid huge financial losses due to extended shut down of production line

Quick Stats

Medical



CNC Machining





European Luxury Automaker

The most innovative companies in the world choose Protolabs

CHALLENGE

- A European luxury high end automotive manufacturer was looking to extend its leadership in high performance vehicles to include electric vehicles
- To optimize the hydraulic system for cooling the battery pack in the company's first ever electric vehicle, it required rapid and innovative solutions in material and design

SOLUTION

- The luxury automaker collaborated with Hutchinson—a leading global design firm and manufacturer—which engaged Protolabs to deliver injection molded components to prototype the hydraulic system
- Protolabs worked closely with Hutchinson to design, validate, and produce different components with specific materials and tight tolerances, minimizing space, and ensuring critical fit

VALUE DELIVERED

- Protolabs delivered parts on demand, meeting the project's stringent timeline and quality standards
- Protolabs' speed, reliability, and quality allowed the customer to obtain parts to-spec for testing and to be mounted on the electric supercar prototype, reducing validation and testing times, and accelerating innovation

Quick Stats












Q3 2023 Overview



Financial Highlights | Q3 2023 YoY

Revenue



Non-GAAP EPS*



• Revenue of \$130.7 million, up 7.1% ¹ YoY

- Record quarterly total revenue
- YoY and QoQ growth in injection molding, CNC machining, 3DP
- Digital network (powered by Hubs) revenue grew 81.2% YoY in constant currencies
- Sequential total revenue growth of 6.9%


Non-GAAP EPS of \$0.51, up \$0.11 YoY

- Third quarter non-GAAP EPS above guidance range, driven by increased volume and gross margin expansion (both factory and network)
- Non-GAAP EPS up \$0.18, or 53.6% sequentially



Revenue by Region | Q3 2023

| | Q3 2023 | Q3 2022 | YoY Change Overall | YoY Change Constant Fx* | YoY Change Constant Fx* Excl. Japan |
|----------|---------|---------|-----------------------|----------------------------|---|
| Americas | \$103.9 | \$99.0 | 5.0% | 5.0% | |
| Europe | \$26.8 | \$21.5 | 24.7% | 16.9% | |
| Japan | - | \$1.3 | (100.0)% | (100.0)% | |
| Total | \$130.7 | \$121.7 | 7.4% | 6.0% | 7.1% |



*YoY change reflected in constant currencies; see reconciliation in appendix



Revenue by Service | Q3 2023 YoY

Injection Molding - Revenue




3D Printing - Revenue



CNC Machining - Revenue



Sheet Metal - Revenue





Revenue by Service | Q3 2023 QoQ

Injection Molding - Revenue




3D Printing - Revenue



CNC Machining - Revenue



Sheet Metal - Revenue





Q3 2023

Detailed Financial Information



Financial Results | Q3 2023

| | Q3 2023 | Q2 2023 | QoQ Change | Q3 2022 | YoY Change |
|---------------------------------|---------|---------|------------|---------|------------|
| Revenue | \$130.7 | \$122.3 | 6.9% | \$121.7 | 7.4% |
| Non-GAAP Gross Margin* | 46.0% | 44.1% | 190 bps | 44.8% | 120 bps |
| Non-GAAP Operating Margin* | 12.5% | 8.9% | 360 bps | 11.2% | 130 bps |
| Non-GAAP Earnings Per Share* | \$0.51 | \$0.33 | 53.6% | \$0.40 | 28.3% |



YoY GAAP to Non-GAAP P&L | Q3 2023

| A | Three Mon | ths End | led September | 30, 2023 | Three Months Ended September 30, 2022 | | | | | | |
|----------------------------|---------------|---------|---------------|-----------|---------------------------------------|---------|-----|----------|-----------|--|--|
| \$ in thousands | GAAP | Adj | justments | Non-GAAP* | | GAAP | Adj | ustments | Non-GAAP* | | |
| Revenue | \$ 130,705 | | – \$ | 130,705 | \$ | 121,721 | | - \$ | 121,721 | | |
| Cost of revenue | 71,423 | | (805) | 70,618 | | 68,089 | | (902) | 67,187 | | |
| Gross profit | \$ 59,282 | \$ | 805 \$ | 60,087 | \$ | 53,632 | \$ | 902 \$ | 54,534 | | |
| Marketing and sales | 21,682 | | (961) | 20,721 | | 20,594 | | (929) | 19,665 | | |
| Research and development | 10,105 | | (675) | 9,430 | | 9,309 | | (602) | 8,707 | | |
| General and administrative | 17,058 | | (3,461) | 13,597 | | 16,477 | | (3,984) | 12,493 | | |
| Closure of Japan business | 22 | | (22) | _ | | 1,194 | | (1,194) | _ | | |
| Total operating expenses | 48,867 | | (5,119) | 43,748 | | 47,574 | | (6,709) | 40,865 | | |
| Income from operations | \$ 10,415 | \$ | 5,924 \$ | | \$ | 6,058 | \$ | 7,611 \$ | 13,669 | | |
| Adjusted EBITDA | N// | A | N/A \$ | 23,938 | | N/ | Α | \$ | 21,959 | | |
| % of Revenue | | | | | | | | | | | |
| Gross Margin | 45.49 | 6 | | 46.0% | | 44.1 | % | | 44.8% | | |
| Marketing and sales | 16.69 | 6 | | 15.9% | | 16.9 | % | | 16.2% | | |
| Research and development | 7.79 | 6 | | 7.2% | | 7.7 | % | | 7.2% | | |
| General and administrative | 13.19 | 6 | | 10.4% | | 13.5 | % | | 10.3% | | |
| Closure of Japan business | - | _ | | _ | | 1.0 | % | | _ | | |
| Total operating expenses | 37.49 | 6 | _ | 33.5% | _ | 39.1 | % | | 33.6% | | |
| Income from operations | 8.09 | 6 | _ | 12.5% | _ | 5.0 | % | | 11.2% | | |
| Adjusted EBITDA | N// | A | | 18.3% | | N/ | A | | 18.0% | | |



QoQ GAAP to Non-GAAP P&L | Q3 2023

| | Three Mon | ths End | ed September | 30, 2023 | Three Months Ended June 30, 2023 | | | | | | |
|----------------------------|---------------|---------|--------------|-----------|----------------------------------|---------|-----|----------|-----------|--|--|
| \$ in thousands | GAAP | Adj | iustments | Non-GAAP* | | GAAP | Adj | ustments | Non-GAAP* | | |
| Revenue | \$ 130,705 | | – \$ | , | \$ | 122,265 | | - \$ | 122,265 | | |
| Cost of revenue | 71,423 | | (805) | 70,618 | | 69,142 | | (803) | 68,339 | | |
| Gross profit | \$ 59,282 | \$ | 805 \$ | 60,087 | \$ | 53,123 | \$ | 803 \$ | 53,926 | | |
| Marketing and sales | 21,682 | | (961) | 20,721 | | 21,730 | | (855) | 20,875 | | |
| Research and development | 10,105 | | (675) | 9,430 | | 9,865 | | (641) | 9,224 | | |
| General and administrative | 17,058 | | (3,461) | 13,597 | | 15,822 | | (2,861) | 12,961 | | |
| Closure of Japan business | 22 | | (22) | _ | | 98 | | (98) | _ | | |
| Total operating expenses | 48,867 | | (5,119) | 43,748 | | 47,515 | | (4,455) | 43,060 | | |
| Income from operations | \$ 10,415 | \$ | 5,924 \$ | 16,339 | \$ | 5,608 | \$ | 5,258 \$ | 10,866 | | |
| Adjusted EBITDA | N/A | ١ | N/A \$ | 23,938 | | N/ | A | \$ | 19,229 | | |
| % of Revenue | | | | | | | | | | | |
| Gross Margin | 45.49 | 6 | | 46.0% | | 43.49 | % | | 44.1% | | |
| Marketing and sales | 16.69 | 6 | | 15.9% | | 17.89 | % | | 17.1% | | |
| Research and development | 7.79 | 6 | | 7.2% | | 8.19 | % | | 7.5% | | |
| General and administrative | 13.19 | 6 | | 10.4% | | 12.99 | % | | 10.6% | | |
| Closure of Japan business | _ | _ | | _ | | 0.19 | % | | _ | | |
| Total operating expenses | 37.49 | 6 | _ | 33.5% | | 38.99 | | | 35.2% | | |
| Income from operations | 8.09 | _ | _ | 12.5% | | 4.69 | _ | | 8.9% | | |
| Adjusted EBITDA | N/A | ١ | | 18.3% | | N/A | Α | | 15.7% | | |



Cash Flow and Balance Sheet | Q3 2023

| \$M | Q3 2023 | Q2 2023 | Q3 2022 |
|-----------------------|---------|---------|---------|
| Operating Cash Flow | \$24.2 | \$9.3 | \$20.5 |
| Capital Expenditures | \$3.1 | \$3.4 | \$10.4 |
| Share Repurchases | \$9.0 | \$8.9 | \$7.8 |
| Cash and Investments* | \$114.9 | \$102.8 | \$113.9 |
| Debt* | \$0 | \$0 | \$0 |



Q4 2023

Financial Outlook



Outlook | Q4 2023

| Q4 2023 Revenue | |
|----------------------------|-----------------|
| Revenue | \$118M - \$126M |
| % Growth YoY (constant FX) | 2% - 8% |

| Q4 2023 Non-GAAP* EPS | |
|-----------------------|-----------------|
| Non-GAAP* EPS | \$0.26 - \$0.34 |
| % Growth YoY | 2% - 33% |

Q4 2023 Outlook Commentary

- Expect foreign currency to have a \$0.5 to \$1.0 million favorable impact on Q4 2023 revenue
- Expect Q4 2023 Non-GAAP* effective tax rate between 19% and 20%
- Expect Q4 2023 diluted shares outstanding of approximately 26 million



Thank You!





Appendix



GAAP to NON-GAAP Reconciliation | Revenue by Region

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Region
(In thousands)
(Unaudited)

| | | | Months End aber 30, 202 | onths Ended er 30, 2023 | | | ree Months Ended ptember 30, 2022 | | |
|---------------|----|---------|---------------------------------|----------------------------|---------|----|--------------------------------------|--------------|----------------------------------|
| | | GAAP | Foreign urrency ¹ | No | on-GAAP | | GAAP | % Change² | % Change Organic ³ |
| Revenues | | | | | | | | | |
| United States | \$ | 103,940 | \$ - | \$ | 103,940 | \$ | 98,970 | 5.0% | 5.0% |
| Europe | | 26,765 | (1,666) | | 25,099 | | 21,464 | 24.7% | 16.9% |
| Japan | | - | - | | - | | 1,287 | (100.0%) | (100.0%) |
| Total revenue | \$ | 130,705 | \$ (1,666) | \$ | 129,039 | \$ | 121,721 | 7.4% | 6.0% |

- 1. Revenue for the three months ended September 30, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
- 2. This column presents the percentage change from GAAP revenue for the three months ended September 30, 2022 to GAAP revenue for the three months ended September 30, 2023.
- 3. This column presents the percentage change from GAAP revenue for the three months ended September 30, 2022 to non-GAAP revenue for the three months ended September 30, 2023 (as recalculated using the foreign currency exchange rates in effect during the three months ended September 30, 2022)) in order to provide a constant-currency comparison.



GAAP to NON-GAAP Reconciliation | Revenue by Service

Proto Labs, Inc.

Comparison of GAAP to Non-GAAP Revenue Growth by Service Line
(In thousands)
(Unaudited)

| | _ | | Ionths End iber 30, 202 | | | | ree Months Ended eptember 30, 2022 | | % Change Organic ³ |
|-------------------|----|---------|--------------------------------|----|---------|------|------------------------------------|--------------|----------------------------------|
| | | GAAP | oreign irrency ¹ | N | on-GAAP | GAAP | | % Change² | |
| Revenues | | | | | | | | | |
| Injection Molding | \$ | 51,688 | \$ (655) | \$ | 51,033 | \$ | 48,940 | 5.6 % | 4.3 % |
| CNC Machining | | 52,916 | (708) | | 52,208 | | 47,489 | 11.4 | 9.9 |
| 3D Printing | | 21,622 | (390) | | 21,232 | | 19,823 | 9.1 | 7.1 |
| Sheet Metal | | 4,291 | (20) | | 4,271 | | 5,219 | (17.8) | (18.2) |
| Other Revenue | | 188 | 107 | | 295 | | 250 | (24.8) | 18.0 |
| Total Revenue | \$ | 130,705 | \$ (1,666) | \$ | 129,039 | \$ | 121,721 | 7.4% | 6.0% |

- 1. Revenue for the three months ended September 30, 2023 has been recalculated using 2022 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
- 2. This column presents the percentage change from GAAP revenue for the three months ended September 30, 2022 to GAAP revenue for the three months ended September 30, 2023.
- 3. This column presents the percentage change from GAAP revenue for the three months ended September 30, 2022 to non-GAAP revenue for the three months ended September 30, 2023 (as recalculated using the foreign currency exchange rates in effect during the three months ended September 30, 2022) in order to provide a constant-currency comparison.



GAAP to NON-GAAP Reconciliation | Gross Margin

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Gross Margin
(In thousands)
(Unaudited)

| | Three Months Ended September 30, | | | | | | |
|----------------------------------|-------------------------------------|----|---------|--|--|--|--|
| | 2023 | | 2022 | | | | |
| Revenue | \$ 130,705 | \$ | 121,721 | | | | |
| Gross profit | 59,282 | | 53,632 | | | | |
| GAAP gross margin | 45.4% | | 44.1% | | | | |
| Add back: | | | | | | | |
| Stock-based compensation expense | 462 | | 560 | | | | |
| Amortization expense | 343 | | 342 | | | | |
| Total adjustments | 805 | | 902 | | | | |
| Non-GAAP gross profit | \$ 60,087 | \$ | 54,534 | | | | |
| Non-GAAP gross margin | 46.0% | | 44.8% | | | | |

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin Excluding Japan (In thousands) (Unaudited)

| | Three Months Ended September 30, | | | | | | | |
|--|-------------------------------------|---------|----|---------|--|--|--|--|
| | | 2023 | | 2022 | | | | |
| Revenue | \$ | 130,705 | \$ | 121,721 | | | | |
| Revenue excluding Japan | \$ | 130,705 | \$ | 120,434 | | | | |
| Gross profit | | 59,282 | | 53,632 | | | | |
| GAAP gross margin | | 45.4% | | 44.1% | | | | |
| Less: Japan gross profit | | - | | 47 | | | | |
| Gross Profit excluding Japan | | 59,282 | | 53,585 | | | | |
| GAAP gross margin excluding Japan | | 45.4% | | 44.5% | | | | |
| Add back: | | | | | | | | |
| Stock-based compensation expense | | 462 | | 560 | | | | |
| Amortization expense | | 343 | | 342 | | | | |
| Less: | | | | | | | | |
| Japan stock-based compensation expense | | - | | 13 | | | | |
| Japan amortization expense | | - | | | | | | |
| Total adjustments | | 805 | | 889 | | | | |
| Non-GAAP gross profit excluding Japan | \$ | 60,087 | \$ | 54,474 | | | | |
| Non-GAAP gross margin excluding Japan | | 46.0% | | 45.2% | | | | |



GAAP to NON-GAAP Reconciliation | Operating Margin

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Operating Margin
(In thousands)
(Unaudited)

| | Three Months Ended September 30, | | | | | |
|---|---|----|---------|--|--|--|
| | 2023 | | 2022 | | | |
| Revenue | \$ 130,705 | \$ | 121,721 | | | |
| Income from operations | 10,415 | | 6,058 | | | |
| GAAP operating margin | 8.0% | | 5.0% | | | |
| Add back: | | | | | | |
| Stock-based compensation expense | 4,441 | | 4,907 | | | |
| Amortization expense | 1,461 | | 1,510 | | | |
| Costs related to Japan closure activities | 22 | | 1,194 | | | |
| Total adjustments | 5,924 | | 7,611 | | | |
| Non-GAAP income from operations | \$ 16,339 | \$ | 13,669 | | | |
| Non-GAAP operating margin | 12.5% | | 11.2% | | | |

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Operating Margin Excluding Japan
(In thousands)
(Unaudited)

| | Three Months Ended September 30, | | | | |
|---|-------------------------------------|---------|------|---------|--|
| | | 2023 | 2022 | | |
| Revenue | \$ | 130,705 | \$ | 121,721 | |
| Revenue excluding Japan | \$ | 130,705 | \$ | 120,434 | |
| Income from operations | | 10,415 | | 6,058 | |
| GAAP operating margin | | 8.0% | | 5.0% | |
| Less: Japan (loss) income from operations | | (7) | | (724) | |
| Income from operations excluding Japan | | 10,422 | | 6,782 | |
| GAAP operating margin excluding Japan | | 8.0% | | 5.6% | |
| Add back: | | | | | |
| Stock-based compensation expense | | 4,441 | | 4,907 | |
| Amortization expense | | 1,461 | | 1,510 | |
| Costs related to Japan closure activities | | 22 | | 1,194 | |
| Less: | | | | | |
| Japan stock-based compensation expense | | - | | 89 | |
| Japan amortization expense | | - | | - | |
| Total adjustments | | 5,924 | | 7,522 | |
| Non-GAAP income from operations excluding Japan | \$ | 16,346 | \$ | 14,304 | |
| Non-GAAP operating margin excluding Japan | | 12.5% | | 11.9% | |



GAAP to NON-GAAP Reconciliation | EBITDA

Proto Labs, Inc. Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA (In thousands) (Unaudited)

| | Three Months Ended September 30, | | | |
|--|-------------------------------------|------|---------|--|
| | 2023 | | 2022 | |
| Revenue | \$ 130,705 | \$ | 121,721 | |
| GAAP net income | 7,954 | | 3,951 | |
| GAAP net income margin | 6.1% | 3.2% | | |
| Add back: | | | | |
| Amortization expense | \$ 1,461 | \$ | 1,510 | |
| Depreciation expense | 7,869 | | 8,197 | |
| Interest income, net | (561) | | (265) | |
| Provision for income taxes | 2,781 | | 2,083 | |
| EBITDA | 19,504 | | 15,476 | |
| EBITDA Margin | 14.9% | | 12.7% | |
| Add back: | | | | |
| Stock-based compensation expense | 4,441 | | 4,907 | |
| Unrealized (gain) loss on foreign currency | (29) | | 382 | |
| Costs related to Japan closure activities | 22 | | 1,194 | |
| Total adjustments | 4,434 | | 6,483 | |
| Adjusted EBITDA | \$ 23,938 | \$ | 21,959 | |
| Adjusted EBITDA Margin | 18.3% | | 18.0% | |




GAAP to NON-GAAP Reconciliation | EPS

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Net Income per Share (In thousands, except share and per share amounts) (Unaudited)

| | Three Months Ended September 30, | | | | |
|---|-------------------------------------|------------|----|------------|--|
| | | 2023 | | 2022 | |
| Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities | | | | | |
| GAAP net income | \$ | 7,954 | \$ | 3,951 | |
| Add back: | | | | | |
| Stock-based compensation expense | | 4,441 | | 4,907 | |
| Amortization expense | | 1,461 | | 1,510 | |
| Unrealized (gain) loss on foreign currency | | (29) | | 382 | |
| Costs related to Japan closure activities | | 22 | | 1,194 | |
| Total adjustments 1 | | 5,895 | | 7,993 | |
| Income tax benefits on adjustments 2 | | (633) | | (1,060 | |
| Non-GAAP net income | Ś | 13,216 | S | 10.884 | |
| Non-GAAP net income per share: | | | | | |
| Basic | S | 0.51 | S | 0.40 | |
| Diluted | \$ | 0.51 | \$ | 0.40 | |
| hares used to compute non-GAAP net income per share: | | | | | |
| Basic | | 26,023,830 | | 27,505,097 | |
| Diluted | | 26,028,456 | | 27,508,217 | |

 Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities were included in the following GAAP consolidated statement of operations categories:

| | Three Months Ended September 30, | | | | | |
|----------------------------|-------------------------------------|-------|----|-------|--|--|
| Cost of revenue | 2023 | | | 2022 | | |
| | \$ | 805 | \$ | 902 | | |
| Marketing and sales | | 961 | | 929 | | |
| Research and development | | 675 | | 602 | | |
| General and administrative | | 3,461 | | 3,984 | | |
| Closure of Japan business | | 22 | | 1,194 | | |
| Total operating expenses | | 5,119 | | 6,709 | | |
| Other income (loss), net | | (29) | | 382 | | |
| Total adjustments | \$ | 5,895 | s | 7,993 | | |





GAAP to NON-GAAP Reconciliation | Q4 2023 Outlook

Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Guidance (In thousands, except share and per share amounts) (Unaudited)

| | Q4 2023 Outlook | | | | |
|--|-----------------|------|------|------|--|
| | Low | | High | | |
| GAAP diluted earnings per share | \$ | 0.07 | \$ | 0.15 | |
| Add back: | | | | | |
| Stock-based compensation expense | | 0.14 | | 0.14 | |
| Amortization expense | | 0.05 | | 0.05 | |
| Unrealized (gain) loss on foreign currency | | 0.00 | | 0.00 | |
| Total adjustments | | 0.19 | | 0.19 | |
| Non-GAAP diluted earnings per share | \$ | 0.26 | \$ | 0.34 | |

